Abstract: In a multi-user, collaborative environment, an operating system state change can occur by passing a stylus pen from one user to another. Upon detecting a change of the active user, a state machine transition can result in a change in a user experience. In one example, a change in the user experience includes a change in user interface (UI) functionality. Some examples include changing color of the digital ink being displayed, changing a handwriting pattern, and automatically switching a view displayed on the user interface. The switched view can be switching from a single-user model to a multi-user model. In another example, a state machine transition can result in establishing connections between devices (e.g., phones or laptops) associated with the users that used the pen.

Abstract: A technique is described herein for decoupling the playback of media content streams that compose a media item. In one implementation, the technique involves: in a synchronized state, presenting a stream of first media content (such as audio content) in synchronization with a stream of second media content (such as video content); detecting a desynchronization event; in response to the desynchronization event, transitioning from the synchronized state to a desynchronized state by changing (e.g., slowing) a rate at which the stream of second media content is presented, relative to the stream of first media content; detecting a resynchronization-initiation event; and, in response to the resynchronization-initiation event, returning to the synchronized state by providing a compressed presentation of the stream of second media content. The technique further involves presenting the stream of first media content at a given non-zero rate while in the desynchronized state.

Abstract: In a multi-user, collaborative environment, an operating system state change can occur by passing a stylus pen from one user to another. Upon detecting a change of the active user, a state machine transition can result in a change in a user experience. In one example, a change in the user experience includes a change in user interface (UI) functionality. Some examples include changing color of the digital ink being displayed, changing a handwriting pattern, and automatically switching a view displayed on the user interface. The switched view can be switching from a single-user model to a multi-user model. In another example, a state machine transition can result in establishing connections between devices (e.g., phones or laptops) associated with the users that used the pen.

Abstract: The present invention relates generally to the field of cancer. In particular, the present invention relates to cancer prognostic and treatment protocols.

Abstract: The present invention relates to a method for determining a prognosis of progression of a cancer in a subject, a method for determining a treatment protocol for a subject having cancer or a method for determining efficacy of a therapeutic treatment of a subject, the method comprising the steps of: (a) assessing a level of a first biomarker selected from at least one of Mcm2-7 in a biological sample from the subject: and (b) assessing the level of a second biomarker selected from at least one of geminin, Aurora A, Plk1, Ki67 and H3S10ph in the biological sample from the subject, wherein the combination of the level of the first biomarker compared to a pre-determined value and the level of the second biomarker compared to a predetermined value is indicative of cancer progression in the subject or is indicative of the treatment regimen prescribed for the subject or is indicative of the efficacy of the therapeutic treatment.

Abstract: The present invention relates to a method for determining a prognosis of progression of a cancer in a subject, a method for determining a treatment protocol for a subject having cancer or a method for determining efficacy of a therapeutic treatment of a subject, the method comprising the steps of: (a) assessing a level of a first biomarker selected from at least one of Mcm2-7 in a biological sample from the subject: and (b) assessing the level of a second biomarker selected from at least one of geminin, Aurora A, Plk1, Ki67 and H3S10ph in the biological sample from the subject, wherein the combination of the level of the first biomarker compared to a pre-determined value and the level of the second biomarker compared to a predetermined value is indicative of cancer progression in the subject or is indicative of the treatment regimen prescribed for the subject or is indicative of the efficacy of the therapeutic treatment.